Pediatrix Medical Group, Inc. (NYSE:MD) Receives $21.00 Consensus PT from Analysts

Pediatrix Medical Group, Inc. (NYSE:MD) has been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat reports. Four analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $21.00.

A number of equities research analysts have recently commented on the stock. Leerink Partners raised their price objective on shares of Pediatrix Medical Group from $14.50 to $17.00 and gave the stock a “market perform” rating in a research note on Friday, September 5th. Wall Street Zen upgraded shares of Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 4th. Zacks Research raised shares of Pediatrix Medical Group from a “hold” rating to a “strong-buy” rating in a report on Friday, November 21st. Weiss Ratings reissued a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Monday. Finally, Truist Financial lifted their price target on Pediatrix Medical Group from $17.00 to $24.00 and gave the company a “hold” rating in a research note on Monday, November 10th.

Insider Activity

In related news, Director Laura A. Linynsky sold 10,000 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $21.65, for a total value of $216,500.00. Following the completion of the sale, the director owned 32,232 shares of the company’s stock, valued at approximately $697,822.80. The trade was a 23.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Mark S. Ordan sold 23,000 shares of the company’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $22.41, for a total transaction of $515,430.00. Following the transaction, the chief executive officer owned 302,805 shares of the company’s stock, valued at $6,785,860.05. This represents a 7.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 43,478 shares of company stock worth $972,924 over the last three months. 0.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Pediatrix Medical Group

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Marshall & Sullivan Inc. WA purchased a new position in Pediatrix Medical Group in the 2nd quarter valued at about $41,000. Canada Pension Plan Investment Board acquired a new position in shares of Pediatrix Medical Group during the second quarter valued at approximately $83,000. AlphaQuest LLC lifted its position in shares of Pediatrix Medical Group by 16.0% in the first quarter. AlphaQuest LLC now owns 5,877 shares of the company’s stock valued at $85,000 after acquiring an additional 811 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Pediatrix Medical Group by 10.6% in the third quarter. Smartleaf Asset Management LLC now owns 6,250 shares of the company’s stock valued at $101,000 after acquiring an additional 601 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Pediatrix Medical Group in the second quarter worth approximately $99,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Price Performance

Shares of MD opened at $21.90 on Wednesday. The business’s 50-day moving average is $20.96 and its two-hundred day moving average is $17.01. The company has a market capitalization of $1.88 billion, a P/E ratio of 11.53 and a beta of 0.77. Pediatrix Medical Group has a fifty-two week low of $11.84 and a fifty-two week high of $24.99. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 1.83.

Pediatrix Medical Group (NYSE:MD) last issued its earnings results on Monday, November 3rd. The company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.21. The firm had revenue of $492.88 million for the quarter, compared to the consensus estimate of $476.45 million. Pediatrix Medical Group had a return on equity of 20.45% and a net margin of 8.44%.The company’s revenue was down 3.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.44 earnings per share. Research analysts predict that Pediatrix Medical Group will post 1.38 earnings per share for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.